Healthcare / BiotechnologyNYSE American
$1.68
-0.10 (-5.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-6.5M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$38M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-125.9%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2006–2025 · 19 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-9.5M · FCF $-8.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||||||
| Net Income | $-9.5M | $-9.5M | $-8.3M | $-8.6M | $-8.1M | $-8.8M | $-13.4M | $-8.4M | $-8.6M | $-10.3M | $-10.7M | $-2.2M | $-13.6M | $-8.9M | $-6.2M | $-6.5M | $-4.7M | $-2.8M | $-2.7M | $-3.1M | $-3.3M |
| EBITDA | $-8.7M | $-8.7M | $-7.5M | $-7.8M | $-7.4M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | -0.63 | -0.63 | -0.70 | -0.74 | -0.70 | -0.81 | — | — | -2.60 | -3.40 | -3.80 | -1.80 | -5.40 | -3.80 | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||||||||
| Debt/Equity | — | — | — | — | 0.00 | — | — | — | — | — | — | 0.00 | 0.21 | 0.00 | 0.00 | — | — | — | — | — | — |
| Current Ratio | 3.17 | 3.17 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||||||
| Free Cash Flow | $-8.5M | $-8.5M | $-6.5M | $-5.8M | $-6.2M | $-8.5M | $-6.7M | $-6.9M | $-8.0M | $-8.1M | $-7.3M | — | — | $-26.0M | $-4.2M | $-4.7M | $-2.6M | — | — | — | — |
| Returns | |||||||||||||||||||||
| ROE | -125.9% | -125.9% | -72.3% | -57.8% | -35.1% | -29.5% | -61.8% | -79.5% | -48.5% | -50.7% | -46.5% | -6.9% | -58.2% | -110.8% | -44.8% | -63.7% | -72.8% | -112.2% | -617.1% | -623.4% | -265.2% |
| Valuation | |||||||||||||||||||||
| P/B | 3.38 | 3.38 | 1.81 | 0.94 | 0.94 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||||||
| EPS Growth | 10.0% | 10.0% | 5.4% | -5.7% | — | — | — | — | 23.5% | 10.5% | -111.1% | 66.7% | -42.1% | — | — | — | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.70 → -0.63
Residual
+10.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.